Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN) announced it will release its financial results for Q2 2022 on August 11, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results. Information regarding the call can be found on Sientra's investor relations website. The Company, headquartered in Santa Barbara, focuses on medical aesthetics, offering innovative products, including FDA-approved breast implants and advanced surgical systems.

Positive

• Sientra's product portfolio includes FDA-approved fifth generation breast implants.
• The company offers innovative products like the Allox2® breast tissue expander.

Negative

• None.

SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 32094933. The webcast link is the following: Sientra Q2' 2022 Earnings Call Webcast Registration Link.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2^® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM^®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com

FAQ

When will Sientra release its Q2 2022 financial results?

Sientra will release its Q2 2022 financial results on August 11, 2022.

What time is Sientra's Q2 2022 earnings call?

The earnings call is scheduled for 4:30 p.m. Eastern Time on August 11, 2022.

Where can I find the webcast for Sientra's earnings call?

The webcast can be found on Sientra's investor relations website.

What products does Sientra offer?

Sientra offers FDA-approved breast implants, the Allox2® breast tissue expander, and the AuraGen fat grafting system.

What is Sientra's focus in the medical aesthetics industry?

Sientra is focused on advancing the art of plastic surgery with innovative products and solutions.